Industry
Biotechnology
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
Loading...
Open
3.15
Mkt cap
39M
Volume
3.9K
High
3.15
P/E Ratio
-1.32
52-wk high
8.19
Low
2.90
Div yield
N/A
52-wk low
2.05
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Insights
October 09, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Insights
October 01, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 11:49 am
Portfolio Pulse from Benzinga Newsdesk
August 16, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
July 08, 2024 | 11:33 am
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 12:49 pm
Portfolio Pulse from ryanfaloona@benzinga.com
June 27, 2024 | 12:37 pm
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 8:16 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.